Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.48 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | HTR7 | P34969 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536570 | 0.93 | EGFR (0.42) | HTR6ELANECTSGPRTN3EGFR | |
| SCHEMBL1136462 | 0.92 | HTR6 (0.47) | HTR6ELANECTSGPRTN3EGFR | |
| SCHEMBL1136524 | 0.91 | HTR6 (0.46) | HTR6ELANECTSGPRTN3EGFR | |
| SCHEMBL4675428 | 0.91 | EGFR (0.39) | HTR6ELANECTSGPRTN3EGFR | |
| SCHEMBL1136505 | 0.91 | HTR6 (0.49) | HTR6ELANECTSGPRTN3EGFR | |
| SCHEMBL4674396 | 0.88 | HTR6 (0.43) | HTR6HTR1AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL4676859 | 0.87 | HTR6 (0.64) | HTR6ELANECTSGPRTN3EGFR | |
| SCHEMBL1136498 | 0.86 | HTR6 (0.45) | HTR6ELANECTSGPRTN3EGFR | |
| SCHEMBL1136500 | 0.84 | HTR6 (0.50) | HTR6EGFRHTR1AHTR7ALDH1A1 | |
| SCHEMBL4674599 | 0.84 | HTR6 (0.52) | HTR6ELANECTSGPRTN3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301625-A2 | Compositions and methods for treating cognitive disorders | F. Hoffmann-La Roche AG (CH) | 2011-03-30 | — | — | EP | claimed |
| EP-1562918-B1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | claimed |
| EP-1799306-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-06-27 | — | — | EP | claimed |
| US-7141562-B2 | Substituted benzoxazinones and uses thereof | ROCHE PALO ALTO LLC (US) | 2006-11-28 | — | — | US | claimed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | claimed |
| EP-1562918-A1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-17 | — | — | EP | claimed |
| WO-2004041792-A1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | claimed |
| US-20040092512-A1 | Substituted benzoxazinones and uses thereof | ROCHE PALO ALTO LLC | 2004-05-13 | — | — | US | claimed |
| EP-2301625-A2 | Compositions and methods for treating cognitive disorders | F. Hoffmann-La Roche AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7713954-B2 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1562918-B1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| EP-1562918-B1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-7141562-B2 | Substituted benzoxazinones and uses thereof | ROCHE PALO ALTO LLC (US) | 2006-11-28 | — | — | US | disclosed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1562918-A1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004041792-A1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
| US-20040092512-A1 | Substituted benzoxazinones and uses thereof | ROCHE PALO ALTO LLC | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | HTR6, HTR2A, HTR2C | HTR6 1/4885ELANE 2954/4885CTSG 1125/4885 |
| US-20040092512-A1 | Substituted benzoxazinones and uses thereof | CYP4X1, CYP3A5, CYP2D6 | HTR6 399/4885ELANE 2237/4885CTSG 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.